Jin Yang Pharmaceutical Balance Sheet Health
Financial Health criteria checks 2/6
Jin Yang Pharmaceutical has a total shareholder equity of ₩118.0B and total debt of ₩85.6B, which brings its debt-to-equity ratio to 72.5%. Its total assets and total liabilities are ₩227.6B and ₩109.6B respectively. Jin Yang Pharmaceutical's EBIT is ₩7.6B making its interest coverage ratio 5.7. It has cash and short-term investments of ₩4.2B.
Key information
72.5%
Debt to equity ratio
₩85.58b
Debt
Interest coverage ratio | 5.7x |
Cash | ₩4.16b |
Equity | ₩118.02b |
Total liabilities | ₩109.58b |
Total assets | ₩227.60b |
Recent financial health updates
These 4 Measures Indicate That Jin Yang Pharmaceutical (KOSDAQ:007370) Is Using Debt Reasonably Well
Aug 12These 4 Measures Indicate That Jin Yang Pharmaceutical (KOSDAQ:007370) Is Using Debt Safely
Feb 11Recent updates
Shareholders Shouldn’t Be Too Comfortable With Jin Yang Pharmaceutical's (KOSDAQ:007370) Strong Earnings
Nov 22Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370) Shares Fly 32% But Investors Aren't Buying For Growth
Aug 19These 4 Measures Indicate That Jin Yang Pharmaceutical (KOSDAQ:007370) Is Using Debt Reasonably Well
Aug 12Jin Yang Pharmaceutical's (KOSDAQ:007370) Problems Go Beyond Weak Profit
May 23A Look At The Intrinsic Value Of Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370)
Mar 22Here's Why I Think Jin Yang Pharmaceutical (KOSDAQ:007370) Is An Interesting Stock
Mar 04These 4 Measures Indicate That Jin Yang Pharmaceutical (KOSDAQ:007370) Is Using Debt Safely
Feb 11Are Jin Yang Pharmaceutical Co., Ltd.'s (KOSDAQ:007370) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
Jan 21Does Jin Yang Pharmaceutical's (KOSDAQ:007370) Share Price Gain of 49% Match Its Business Performance?
Jan 04We're Not So Sure You Should Rely on Jin Yang Pharmaceutical's (KOSDAQ:007370) Statutory Earnings
Dec 17Here's Why We Think Jin Yang Pharmaceutical (KOSDAQ:007370) Is Well Worth Watching
Nov 30Financial Position Analysis
Short Term Liabilities: A007370's short term assets (₩43.7B) exceed its short term liabilities (₩20.7B).
Long Term Liabilities: A007370's short term assets (₩43.7B) do not cover its long term liabilities (₩88.9B).
Debt to Equity History and Analysis
Debt Level: A007370's net debt to equity ratio (69%) is considered high.
Reducing Debt: A007370's debt to equity ratio has increased from 21.1% to 72.5% over the past 5 years.
Debt Coverage: A007370's debt is not well covered by operating cash flow (18.3%).
Interest Coverage: A007370's interest payments on its debt are well covered by EBIT (5.7x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/20 07:42 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jin Yang Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|